Neoplasms

All Conditions

Symptoms and General Pathology

Carcinoma

Neoplasm Metastasis

Syndrome

Carcinoma, Basal Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Basal Cell

Capsules, Oral, 30 mg starting; dose escalation, Once daily, 37 days; additional days if receiving benefit

BMS-833923 (XL139)

Bristol-Myers Squibb

The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule

A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

A Phase 1 Multiple Ascending Dose Study of BMS-833923 in Subjects With Advanced or Metastatic Solid Tumors

Use NCI CTCAE to monitor safety assessments including physical findings, laboratory tests, and radiographic assessments to establish the maximum tolerated dose and recommended Phase 2 dose range and schedule of BMS-833923

glioma-associated oncogene family of transcription factors (GLI)

Tumor assessments by computed tomography (CT)

The results of vital sign measurements, electrocardiogram (ECGs), pulmonary function tests, multigated radionuclide angiography (MUGA) or echocardiograms, physical examinations, and clinical laboratory tests

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer	NCT00670189	Hedgehog Pathwa... Smoothened Basal Cell Carc... Basal Cell Nevo...	BMS-833923 (XL1...	18 Years -	Bristol-Myers Squibb
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer	NCT00670189	Hedgehog Pathwa... Smoothened Basal Cell Carc... Basal Cell Nevo...	BMS-833923 (XL1...	18 Years -	Bristol-Myers Squibb

Spots Global Cancer Trial Database for basal cell nevoid syndrome (bcns)